An Open-Label, Extension Study of the Effects of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)

Trial Profile

An Open-Label, Extension Study of the Effects of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs TRx 0237 (Primary)
  • Indications Alzheimer's disease; Dementia
  • Focus Adverse reactions; Registrational
  • Sponsors TauRx Therapeutics
  • Most Recent Events

    • 02 Aug 2017 This trial has been discontinued in Netherlands.
    • 19 Jul 2017 This trial has been discontinued in Croatia (End date: 2017-05-08).
    • 11 Jul 2017 This trial has been discontinued in Spain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top